Table 1.
Demographic and biochemical characteristics in the study population.
| All subjects (n = 50) |
Without AKI (n = 28) |
With AKI (n = 22) |
|
|---|---|---|---|
| Age (months)* | 6.00 (4.00–7.00) | 3.3 (2.37–4.40) | 11.7 (7.07–18.12) |
| Gender, male (%) | 56 | 61.5 | 38.5 |
| BMI (kg/m2) | 11.67 ± 4.29 | 10.36 ± 2.02 | 12.88 ± 5.69a |
| Fever (°C) | 39.22 ± 0.658 | 39.17 ± 0.58 | 39.22 ± 0.77 |
| Duration of fever (days) | 3.1 ± 1.45 | 2.74 ± 1.29 | 3.75 ± 1.52a |
| Duration in hospital (days)* | 5.46 (5.00–6.00) | 5.41 (4.24–6.90) | 5.89 (5.21–7.61) |
| GFR (mL/min/m2) | 49.20 ± 13.34 | 51.13 ± 10.07 | 40.42 ± 12.49 |
| sCr (µmol/L) | 57.85 ± 13.99 | 50.70 ± 7.56 | 65.40 ± 15.60 |
| Urea (mmol/L)* | 2.87 (2.50–3.31) | 2.47 (2.06–2.98) | 3.40 (2.61–4.42)a |
| Leukocyte number (×10e9/L) | 17.55 ± 5.92 | 16.38 ± 5.16 | 19.12 ± 6.5a |
| Urine culture (%) | |||
| Escherichia coli | 88 | 90.9 | 85.0 |
| Klebsiella | 4.8 | 4.5 | 5 |
| Proteus | 4.8 | 0 | 10 |
| Other | 2.4 | 4.5 | 0 |
| Therapy (%) | |||
| Longaceph (ceftriaxone) | 38.6 | 39.1 | 38.1 |
| Amikacin | 36.4 | 30.4 | 42.9 |
| Combination | 25.0 | 30.5 | 19.0 |
Data are mean ± SD, percentages, or *geometrical mean (95% CI for the mean) for variables with skewed distribution. asignificantly different from group without AKI by Student t-test.